A study of bone metabolism using an anti RANKL antibody-treated mouse model.
Description: An anti-bone-resorptive drug Denosumab, an anti-RANKL antibody, is used to treat adults' bone disease because of its inhibitory effect of osteoclast differentiation. However, the precise effect of anti-RANKL antibody in younger patients are unknown. In the present study, we analyzed the effect of anti-RANKL antibody on growth and bone metabolism in young mice. Newborn mice exposed to the antibody in utero were normally born, but died within 24 h after birth. Mice, which were treated with anti-RANKL antibody at 1-week-old, showed decreased osteoclastogenesis and increased bone mass at the age of 2 weeks. However, at the age of 8 weeks, mice showed normal body length, body weight and tooth development. These results suggest that an anti-RANKL antibody is safety and efficacious in young patients.
Amount: ¥3,900,000
Funding type: fellowship
Funder scheme: Grant-in-Aid for Young Scientists (B)
Start date: 2016-04-01
End date: 2018-03-31
Investigator: Akiko Karakawa
Institution: Showa University
Funded outputs count: 6
Funder award ID: 16K20655
OpenAlex ID: G773281031